Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

Status:
Completed

Trial end date:
2015-09-01

Target enrollment:

Participant gender:

This is an open-label, multiple dose, PK and safety study in patients with chronic, stable schizophrenia or schizoaffective disorder.

Phase 1

Zogenix, Inc.

Risperidone